NASDAQ:CRIS Curis (CRIS) Stock Forecast, Price & News $5.80 -0.79 (-11.99%) (As of 02:18 PM ET) Add Compare Share Share Today's Range$5.75▼$6.5750-Day Range$7.60▼$131.8052-Week Range$5.75▼$20.00Volume69,224 shsAverage Volume20,851 shsMarket Capitalization$34.16 millionP/E RatioN/ADividend YieldN/APrice Target$90.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Curis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,435.8% Upside$90.00 Price TargetShort InterestBearish22.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($9.33) to ($8.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector838th out of 969 stocksBiological Products, Except Diagnostic Industry140th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $90.00, Curis has a forecasted upside of 1,435.8% from its current price of $5.86.Amount of Analyst CoverageCuris has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.58% of the outstanding shares of Curis have been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Curis has recently increased by 14.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRIS. Previous Next 1.6 News and Social Media Coverage News SentimentCuris has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Curis this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Curis to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.81% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 25.41% of the stock of Curis is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($9.33) to ($8.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Curis (NASDAQ:CRIS) StockCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Read More CRIS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRIS Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comCuris (NASDAQ:CRIS) Hits New 52-Week Low at $6.00September 29, 2023 | markets.businessinsider.comBuy Rating for Curis (CRIS) Amidst Reverse Stock Split and Revised Launch Estimates for Key Product, EmavusertibOctober 2, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 28, 2023 | americanbankingnews.comHC Wainwright Weighs in on Curis, Inc.'s FY2023 Earnings (NASDAQ:CRIS)September 26, 2023 | thestreet.comCuris Reaches New 52-Week High (CRIS)September 26, 2023 | americanbankingnews.comCuris (NASDAQ:CRIS) Given "Buy" Rating at HC WainwrightSeptember 26, 2023 | americanbankingnews.comCuris (NASDAQ:CRIS) Receives New Coverage from Analysts at StockNews.comSeptember 25, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Curis (CRIS) Buy RecommendationOctober 2, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 25, 2023 | markets.businessinsider.comAnalyst Ratings for CurisSeptember 25, 2023 | markets.businessinsider.comPromising Developments in Curis’s AML and MDS Treatment Research Bolster Buy Rating: A Detailed Look at Emavusertib’s PotentialSeptember 12, 2023 | finance.yahoo.comCuris Announces Date for the 2nd Symposium on IRAK4 in CancerSeptember 10, 2023 | ftw.usatoday.comNFL fans roasted Cris Collinsworth for trying to argue that Patrick Mahomes is underratedSeptember 7, 2023 | markets.businessinsider.comExpert Ratings for CurisAugust 17, 2023 | technews.tmcnet.comOne of America's Fastest Growing Healthcare Groups, Curis Functional Health, Partners With Adonis to Centralize Revenue OperationsAugust 5, 2023 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | msn.comCuris (CRIS) Reports Q2 Loss, Misses Revenue EstimatesAugust 3, 2023 | washingtonpost.comCuris: Q2 Earnings SnapshotAugust 3, 2023 | msn.comCuris (CRIS) Price Target Decreased by 11.11% to 6.12August 3, 2023 | finance.yahoo.comCuris Provides Second Quarter 2023 Business UpdateJuly 28, 2023 | finance.yahoo.comCuris to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023July 11, 2023 | msn.comCantor Fitzgerald Reiterates Curis (CRIS) Overweight RecommendationJuly 7, 2023 | markets.businessinsider.comAnalyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia StudyJuly 7, 2023 | msn.comHC Wainwright & Co. Maintains Curis (CRIS) Buy RecommendationJuly 6, 2023 | seekingalpha.comCuris launches ~$15.1M registered direct offeringJuly 6, 2023 | markets.businessinsider.comCuris: FDA Removes Partial Clinical Hold On TakeAim Leukemia StudyJuly 6, 2023 | msn.comCuris says FDA lifted partial clinical hold on leukemia trialSee More Headlines Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CRIS CUSIP23126910 CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees51Year Founded2000Price Target and Rating Average Stock Price Forecast$90.00 High Stock Price Forecast$120.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside+1,351.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($10.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,670,000.00 Net Margins-471.71% Pretax Margin-471.71% Return on Equity-116.63% Return on Assets-46.90% Debt Debt-to-Equity RatioN/A Current Ratio7.01 Quick Ratio7.01 Sales & Book Value Annual Sales$10.16 million Price / Sales3.59 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / Book0.64Miscellaneous Outstanding Shares5,890,000Free Float5,602,000Market Cap$36.52 million OptionableOptionable Beta3.04 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. James E. Dentzer (Age 56)Pres, CEO & Director Comp: $912.29kMs. Diantha Duvall CPA (Age 51)M.B.A., CFO, Treasurer, Assistant Sec., Principal Financial Officer & Principal Accounting Officer Comp: $588.95kMr. Mark W. Noel (Age 64)VP of Technology Management & Intellectual Property Ms. Elif McDonaldVP of Investor Relations & Corp. CommunicationsDr. Reinhard Wilhelm von Roemeling M.D.Sr. VP of Clinical Devel.Dr. Jonathan B. Zung Ph.D. (Age 58)Chief Devel. Officer More ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSAcorda TherapeuticsNASDAQ:ACORSangamo TherapeuticsNASDAQ:SGMOOKYO PharmaNASDAQ:OKYOSorrento TherapeuticsNASDAQ:SRNEView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 200 shares on 8/15/2023Ownership: 0.000%M28 Capital Management LPBought 1,517,858 shares on 8/11/2023Ownership: 5.097%Renaissance Technologies LLCBought 53,835 shares on 8/11/2023Ownership: 1.428%BlackRock Inc.Sold 216,224 shares on 8/11/2023Ownership: 0.995%Northern Trust CorpSold 29,124 shares on 8/11/2023Ownership: 0.130%View All Institutional Transactions CRIS Stock - Frequently Asked Questions Should I buy or sell Curis stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks. What is Curis' stock price forecast for 2023? 2 equities research analysts have issued 12 month price objectives for Curis' shares. Their CRIS share price forecasts range from $60.00 to $120.00. On average, they expect the company's share price to reach $90.00 in the next twelve months. This suggests a possible upside of 1,351.6% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts. How have CRIS shares performed in 2023? Curis' stock was trading at $11.00 at the beginning of the year. Since then, CRIS stock has decreased by 43.6% and is now trading at $6.1999. View the best growth stocks for 2023 here. Are investors shorting Curis? Curis saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,330,000 shares, an increase of 14.7% from the August 31st total of 1,160,000 shares. Based on an average trading volume of 324,500 shares, the short-interest ratio is presently 4.1 days. View Curis' Short Interest. When is Curis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CRIS earnings forecast. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($2.40). The biotechnology company earned $2.20 million during the quarter, compared to analysts' expectations of $2.57 million. Curis had a negative trailing twelve-month return on equity of 116.63% and a negative net margin of 471.71%. When did Curis' stock split? Shares of Curis reverse split on the morning of Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK). What is Curis' stock symbol? Curis trades on the NASDAQ under the ticker symbol "CRIS." How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Curis' stock price today? One share of CRIS stock can currently be purchased for approximately $6.20. How much money does Curis make? Curis (NASDAQ:CRIS) has a market capitalization of $36.52 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. How can I contact Curis? Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501. This page (NASDAQ:CRIS) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.